Hereditary Cancer Genetic Testing


Supporting your practice and patients with identifying and managing hereditary cancer


Hereditary cancer screening is crucial for the early detection of certain cancers, assessing risk, and improving patient outcomes.1

  • Approximately 1 in 4 women who visit an OB/GYN meet guideline criteria for further evaluation and testing2-4
  • Up to 10% of all cancers may be caused by inherited genetic changes5
  • Up to 10% of breast cancer patients6 and up to 23% of ovarian cancer patients7-8 have these genetic changes



Hereditary cancer genetic testing


As a trusted partner for hereditary cancer solutions, we provide genetic testing, digital tools, and support to help you implement a hereditary cancer risk assessment program at your practice to provide patients with personalized health insights.

  • Flexible multi-gene panels with a competitive turnaround time (TAT), typically within 14-21 days, or 8-10 days rush for certain panels
  • Comprehensive post-test genetic counseling for non-negative results
  • Digital family history questionnaire personalized for your practice



Panel options

Our panels include all hereditary cancer genes with guideline-based risk and management recommendations to ensure a comprehensive screening. For OB/GYN practices, the most frequently ordered Hereditary Cancer panel is our 38-gene Common Cancer Panel, which has been carefully curated to cover well-documented genes linked to multiple cancer types.

Common Cancer Management Panel:

      • 38 genes designed to maximize the diagnostic yield for the most common forms of hereditary cancer, including breast, colon, uterine, ovarian, and pancreatic cancers
      • All genes are either guideline-driven or have well-established evidence of increased risk for common cancers
      • Majority of genes are clinically actionable


Comprehensive Common Cancer Panel:

      • 49 genes associated with known or possible increased risk of hereditary cancer across the major organ systems


Breast/Gyn Cancer Panel:

      • 24 genes associated with increased risk for breast, ovarian and uterine cancers, the majority with published management guidelines


We also offer a range of other panels that may be appropriate for your patients. View our Panel Guide for full details on all Hereditary Cancer panels.


Best-in-class support and service, every step of the way

Our comprehensive workflow options can seamlessly integrate with your practice and our highly knowledgeable team is dedicated to partnering with practices such as yours to deliver the best possible care to patients.

Provider Support

  • Flexible ordering and workflow integrations
  • Competitive turnaround time (TAT), typically within 14-21 days, or 8-10 days rush for certain panels
  • Reports include your patients’ results and the resources for medical management recommendations
  • Post-test counseling available for patients with non-negative results


Patient Support

  • Counseling provided by board-certified genetic counselors, if applicable
  • Pre- and post-test videos developed by our genetic counselors for patient education and support
  • In-network with most regional and national payers, benefits investigation and patient financial support
  • Commitment to helping patients understand testing and implications for the prevention and active management of cancer



Getting Started




When to order Hereditary Cancer genetic testing

Ordering options available via Provider Portal or paper

  • Place an order through the Provider Portal (log in or create a new account)
  • Or search for a test in our catalog and submit a test requisition form via fax or email. For more information, please call us directly at 888-729-1206 (option 3), or email



Hereditary Cancer
Family History Questionnaire

Designed to help your patients assess their risk of hereditary cancer. For more information on how to implement this questionnaire within your practice, our customer service team is happy to help. Call us directly at 888-729-1206 (option 3), or email

View Digital Questionnaire

Paper versions: English | Spanish

Pre-test educational video

If you believe that a hereditary cancer test is right for your patient, you may ask your patient to watch this informational video to learn more about the testing process.

Sema4 celebrates Gynecologic Awareness Month

September is Gynecologic Cancer Awareness Month, a month dedicated to raising awareness of cancers that can affect the female reproductive system.  Sema4 offers hereditary cancer testing solutions to help identify a person’s potential for developing a gynecologic cancer, including a brief online Hereditary Cancer Family History Questionnaire to help ensure patients in need of further surveillance are not missed and a variety of panel options should a patient meet criteria for further testing.

Watch Dr. Marra Francis, Head of Medical Affairs for Women’s Health at Sema4,
discuss the importance of hereditary testing protocols in the OB/GYN setting,
as recommended by USPSTF and ACOG.

For more, go to The Sema4 Network to watch
“CATCHING CANCER EARLY: Assessing the need for and
effectively implementing a care delivery model for hereditary cancer.”

Want to get involved?

The convenient kit below includes the Patient Information Card, social media posts, and email templates customizable for your practice so patients can:

  • Understand the importance of knowing their hereditary cancer risk
  • Learn how your practice can help support their care
  • Take steps to understand if hereditary cancer testing may be appropriate for them

How to choose the right kit
to fit your needs


If you would like to use GeneScreen (GS), a genetic counseling service that will be available to your patients after they complete their Hereditary Cancer Family History Questionnaire. If you already have in-house genetic counseling, please download the Non-GS kit instead.


Connect with us today

Our customer service team is available to answer any questions you may have. Call us directly at 888-729-1206 (option 3), or email


1. ACOG Hereditary Cancer Syndromes and Risk Assessment. ACOG COMMITTEE OPINION SUMMARY, Number 793. Obstetrics & Gynecology: December 2019 – Volume 134 – Issue 6 – p 1366-1367.; 2. Lindsay Dohany, et al. Hereditary cancer risk assessment using a chatbot in women presenting to obstetrics and gynecology practices across the U.S. [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-08-39.; 3. Frezzo, T., et al. The genetic family history as a risk assessment tool in internal medicine. Genet Med 5, 84–91 (2003).; 4. DeFrancesco MS, et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstet Gynecol. 2018 Nov;132(5):1121-1129.; 5. The National Cancer Institute: The Genetics of Cancer. August 17, 2022; 6. Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, Sharma L, Saam J, Lancaster J, Daly MB. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017 May 15;123(10):1721-1730.; 7. Walsh T., Casadei S., Lee M. K., et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(44):18032–18037.; 8. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807–16.